AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33034421 — intervention group
Group type: COMPARATOR
Intervention: Injection vs Nuvaring®
Number of subjects: 130
Study 33034421 — intervention group
Group type: COMPARATOR
Intervention: Injection vs COC
Number of subjects: 130
Study 34370172 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Phaco)
Number of subjects: 33
Study 34370172 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy (PT)
Number of subjects: 33
Study 32877599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (150 mg twice daily and 2 mg once daily respectively)
Number of subjects: 870
Study 32877599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 616117792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue (bimatoprost 0.01%)
Number of subjects: 19
Study 616117792 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (contralateral eye)
Number of subjects: 19
Study 32485993 — intervention group
Group type: EXPERIMENTAL
Intervention: 430 mg green oat extract
Number of subjects: 132
Study 32485993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1290 mg green oat extract
Number of subjects: 132
Study 32485993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1290 mg green oat extract (after four weeks)
Number of subjects: 132
Study 32485993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1290 mg green oat extract
Number of subjects: 132
Study 32485993 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weeks of supplementation with 430 mg and 1290 mg green oat extract
Number of subjects: 132
Study 32485993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 35894434 — intervention group
Group type: COMPARATOR
Intervention: Control (no PFMT)
Number of subjects: 104
Study 33552234 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU subcutaneous growth hormone (GH) administered every other day for 3 months
Number of subjects: 16
Study 33552234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33552234 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU subcutaneous growth hormone (GH)
Number of subjects: 16
Study 33004679 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper‐ and lower‐body compression garments (COMP)
Number of subjects: 7
Study 33004679 — intervention group
Group type: COMPARATOR
Intervention: Standard winter‐biathlon racing suit (CON)
Number of subjects: 7
Study 35276771 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day food diaries (reference method)
Number of subjects: 0
Study 35276771 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency meal counts from 7 day food diaries
Number of subjects: 0
Study 35276771 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day dietary recalls using standard estimated portion sizes
Number of subjects: 0
Study 35276771 — intervention group
Group type: COMPARATOR
Intervention: Meat reduction intervention
Number of subjects: 0
Study 32555024 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing snacks (SS; 8 × 15-30 s once per hour)
Number of subjects: 23
Study 32555024 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED; 9-h sitting)
Number of subjects: 23
Study 32896955 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational application for 30 days
Number of subjects: 0
Study 32896955 — intervention group
Group type: COMPARATOR
Intervention: Control application for 30 days
Number of subjects: 0
Study 32896955 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 35990242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 309
Study 35990242 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 309
Study 32429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body iron stores at baseline
Number of subjects: 1223
Study 32429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline iron status
Number of subjects: 1223
Study 32429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 1223
Study 35599458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVTpri)
Number of subjects: 540
Study 35599458 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MMpri)
Number of subjects: 540
Study 35599458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVTpri) in patients with target mismatch
Number of subjects: 540
Study 35599458 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MMpri) in patients with target mismatch
Number of subjects: 540
Study 35599458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVTpri) without target mismatch
Number of subjects: 540
Study 35599458 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MMpri) without target mismatch
Number of subjects: 540
Study 34290863 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein-based multi-ingredient nutritional drink (WD)
Number of subjects: 15
Study 32478400 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot GnRHa protocol
Number of subjects: 819
Study 32478400 — intervention group
Group type: COMPARATOR
Intervention: Long GnRHa protocol
Number of subjects: 819
Study 32478400 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 819
Study 35763704 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Number of subjects: 454
Study 35763704 — intervention group
Group type: COMPARATOR
Intervention: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Number of subjects: 454
Study 35763704 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Number of subjects: 454
Study 35763704 — intervention group
Group type: COMPARATOR
Intervention: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Number of subjects: 454
Study 35763704 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 454
Study 32747995 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry (WBB) drink
Number of subjects: 35
Study 32747995 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 35
Study 34480632 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline administration
Number of subjects: 14
Study 34480632 — intervention group
Group type: COMPARATOR
Intervention: sham intervention
Number of subjects: 14
Study 33872801 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive preventive intervention including point of care testing for early infant HIV diagnosis and maternal viral load, and infant single-drug Pre-Exposure Prophylaxis (lamivudine) if mothers are virally unsuppressed.
Number of subjects: 2000
Study 33872801 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention based on the national PMTCT guidelines for HIV-1 uninfected exposed breastfeeding infants.
Number of subjects: 2000
Study 32633995 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention training on consultation skills
Number of subjects: 64
Study 32633995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no QI intervention)
Number of subjects: 64
Study 32633995 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-year students
Number of subjects: 64
Study 36241476 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (MG+)
Number of subjects: 200
Study 36241476 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplementation (MG−)
Number of subjects: 200
Study 35902190 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational redesign based on the Magnet model
Number of subjects: 60
Study 35902190 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 60
Study 35902190 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional data collection on perceived work environments, patient safety, and patient quality of care
Number of subjects: 60
Study 34684517 — intervention group
Group type: EXPERIMENTAL
Intervention: MNPs containing 10 mg of zinc
Number of subjects: 100
Study 34684517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablet containing 10 mg zinc
Number of subjects: 100
Study 34684517 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 100
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookah smoking
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of smoking effects (boys)
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of smoking effects (girls)
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intention
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards smoking
Number of subjects: 1075
Study 33112564 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cigarette smoke
Number of subjects: 1075
Study 34505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite restorative system without selective enamel conditioning (Group I)
Number of subjects: 50
Study 34505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite restorative system with selective enamel conditioning (Group II)
Number of subjects: 50
Study 34505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement without EDTA pretreatment (Group III)
Number of subjects: 50
Study 34505916 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement with EDTA pretreatment (Group IV)
Number of subjects: 50
Study 33213446 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based breastfeeding-related information
Number of subjects: 1000
Study 33213446 — intervention group
Group type: COMPARATOR
Intervention: Non-breastfeeding information via WeChat
Number of subjects: 1000
Study 36093105 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 85
Study 36093105 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions
Number of subjects: 85
Study 33153912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counseling when dispensing naloxone by standing order
Number of subjects: 45
Study 33153912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 33141825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 238
Study 33141825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 32825981 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 45
Study 32825981 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Number of subjects: 45
Study 32825981 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional physical therapy)
Number of subjects: 45
Study 35726887 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care gown plus a single-use undergarment with retractable panels and releasable waistband
Number of subjects: 200
Study 35726887 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care gown only
Number of subjects: 200
Study 32966959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 80
Study 32966959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 80
Study 36098519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensitrelvir 125 mg
Number of subjects: 69
Study 36098519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensitrelvir 250 mg
Number of subjects: 69
Study 36098519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 33714618 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum preservation
Number of subjects: 225
Study 33714618 — intervention group
Group type: COMPARATOR
Intervention: Total omentectomy
Number of subjects: 225
Study 32710741 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (>2.1 g · kg LBM‐1 · d‐1)
Number of subjects: 12
Study 32710741 — intervention group
Group type: COMPARATOR
Intervention: Recommended protein intake (1.1 g · kg LBM‐1 · d‐1)
Number of subjects: 12
Study 35473809 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) prophylaxis
Number of subjects: 120
Study 35473809 — intervention group
Group type: COMPARATOR
Intervention: Nonprophylaxis (Control)
Number of subjects: 120
Study 33160319 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished group
Number of subjects: 353
Study 33160319 — intervention group
Group type: COMPARATOR
Intervention: Normal nutrition status group
Number of subjects: 353
Study 36121686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer along with combination HIV prevention (CHP) interventions
Number of subjects: 3026
Study 36121686 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving solely CHP interventions
Number of subjects: 3026
Study 34044875 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg neflamapimod, orally twice daily for 24 weeks
Number of subjects: 161
Study 34044875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 32662069 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (n = 14)
Number of subjects: 30
Study 32662069 — intervention group
Group type: COMPARATOR
Intervention: Control group (cognitive training of executive function and memory, n = 16)
Number of subjects: 30
Study 32662069 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 30
Study 36175314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training group (ATG)
Number of subjects: 49
Study 36175314 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 49
Study 36175314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ATG and CG)
Number of subjects: 49
Study 32085394 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (dapagliflozin: up to 10 mg/day)
Number of subjects: 50
Study 32085394 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling
Number of subjects: 50
Study 32085394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35385695 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 20 mg
Number of subjects: 753
Study 35385695 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg
Number of subjects: 753
Study 35385695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled asundexian
Number of subjects: 753
Study 35385695 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 753
Study 33984316 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Heart Failure Mortality Risk Grade simultaneous 7‐ and 30‐day (EHMRG30‐ST) risk scores and rapid outpatient follow‐up (RAPID‐HF) clinic for low‐to‐intermediate risk patients.
Number of subjects: 10
Study 33984316 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMRG30‐ST web calculator access and referral to the RAPID‐HF clinic facilitated by a study nurse navigator.
Number of subjects: 10
Study 33984316 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID‐HF clinic care during the 30‐day transition after hospital separation.
Number of subjects: 10
Study 32100607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 44
Study 35691282 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg per day of N-Acetyl-Cysteine (NAC) for 12 weeks
Number of subjects: 68
Study 35691282 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of Selenium (Se) per day for 12 weeks
Number of subjects: 68
Study 35691282 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of Selenium (Se) and 600 μg of NAC per day for 12 weeks
Number of subjects: 68
Study 35691282 — intervention group
Group type: COMPARATOR
Intervention: Placebo of Se and NAC for 12 weeks
Number of subjects: 68
Study 35691282 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 68
Study 33586455 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Chat intervention (4-week family group chat)
Number of subjects: 41
Study 32050222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral moxifloxacin 500 μg
Number of subjects: 25
Study 32050222 — intervention group
Group type: COMPARATOR
Intervention: Intracameral moxifloxacin 250 μg
Number of subjects: 25
Study 35697641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphilimus-eluting stent (AES)
Number of subjects: 0
Study 35697641 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 0
Study 32538282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 0
Study 34628408 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 262
Study 34628408 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA)
Number of subjects: 262
Study 32065922 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaves from the outside position
Number of subjects: 15
Study 32065922 — intervention group
Group type: COMPARATOR
Intervention: Leaves from within the canopy position
Number of subjects: 15
Study 32065922 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside canopy leaves
Number of subjects: 15
Study 32065922 — intervention group
Group type: COMPARATOR
Intervention: Within canopy leaves
Number of subjects: 15
Study 32065922 — intervention group
Group type: EXPERIMENTAL
Intervention: Photosynthetic parameters (A, gs, Ci, T, WUEi, WUEins)
Number of subjects: 15
Study 32065922 — intervention group
Group type: COMPARATOR
Intervention: Reduced photosynthetic efficiency within the canopy
Number of subjects: 15
Study 35595193 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM (n=273)
Number of subjects: 231
Study 35595193 — intervention group
Group type: COMPARATOR
Intervention: IVF (n=273)
Number of subjects: 231
Study 33226575 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIS-T (n=44)
Number of subjects: 83
Study 33226575 — intervention group
Group type: COMPARATOR
Intervention: Active comparison control (n=39)
Number of subjects: 83
Study 32293374 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing screen media use by handing over portable devices for 2 weeks and limiting entertainment-based screen media use to no more than 3 hours/week/person.
Number of subjects: 95
Study 32293374 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic mobile phones (not smartphones) provided during the intervention period.
Number of subjects: 95
Study 32293374 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of physical activity using two triaxial accelerometers.
Number of subjects: 95
Study 32293374 — intervention group
Group type: EXPERIMENTAL
Intervention: Single channel EEG-based sleep monitor system used for sleep assessment.
Number of subjects: 95
Study 32293374 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological stress parameters assessed in adults.
Number of subjects: 95
Study 34463466 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention - alarm cues
Number of subjects: 0
Study 34463466 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention - time cues
Number of subjects: 0
Study 34463466 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention - restructuring the physical environment
Number of subjects: 0
Study 34463466 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention - social support
Number of subjects: 0
Study 32403938 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional consultation with a specialist preventive care clinician
Number of subjects: 811
Study 32403938 — intervention group
Group type: COMPARATOR
Intervention: Usual care (preventive care in routine consultations)
Number of subjects: 811
Study 34822950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aqueous sodium hypochlorite (SH)
Number of subjects: 239
Study 34822950 — intervention group
Group type: COMPARATOR
Intervention: SH preceded by 70% ethanol (ET‐SH)
Number of subjects: 239
Study 34162484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose (FDI) 1,000 mg
Number of subjects: 1525
Study 34162484 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS) 200 mg (up to 5 doses, recommended cumulative dose 1,000 mg)
Number of subjects: 1525
Study 32102472 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaoke training (once a week for two hours, with an hour of homework assigned weekly)
Number of subjects: 26
Study 32102472 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaoke training
Number of subjects: 26
Study 32102472 — intervention group
Group type: COMPARATOR
Intervention: Scratch art training (active control group)
Number of subjects: 26
Study 35933083 — intervention group
Group type: EXPERIMENTAL
Intervention: δ‐tocotrienol 300 mg twice daily for 48 weeks
Number of subjects: 100
Study 35933083 — intervention group
Group type: COMPARATOR
Intervention: α‐tocopherol 268 mg twice daily for 48 weeks
Number of subjects: 100
Study 33533878 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of 2 mA anodal tDCS to visual cortex contralateral to visual stimuli
Number of subjects: 0
Study 33533878 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 33533878 — intervention group
Group type: COMPARATOR
Intervention: 20 minutes of 2 mA anodal tDCS to visual cortex ipsilateral to visual stimuli
Number of subjects: 0
Study 32134977 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging smoking cessation intervention
Number of subjects: 0
Study 32134977 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34515149 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide (TAA)
Number of subjects: 260
Study 34515149 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP)
Number of subjects: 260
Study 32029499 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 mg folic acid with 60 mg iron weekly for 16 weeks
Number of subjects: 300